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The Human Interferon-Induced MxA Protein Inhibits Early Stages of
Influenza A Virus Infection by Retaining the Incoming Viral Genome
in the Cytoplasm
Han Xiao,a* Marian J. Killip,a Peter Staeheli,b Richard E. Randall,a David Jacksona
Biomolecular Sciences Research Complex, University of St Andrews, North Haugh, St Andrews, United Kingdoma; Institute for Virology, University Medical Center Freiburg,
Freiburg, Germanyb
The induction of an interferon-induced antiviral state is a powerful cellular response against viral infection that limits viral
spread. Here, we show that a preexisting antiviral state inhibits the replication of influenza A viruses in human A549 cells by pre-
venting transport of the viral genome to the nucleus and that the interferon-inducedMxA protein is necessary but not sufficient
for this process. This represents a previously unreported antiviral function of MxA against influenza A virus infection.
The production of interferons (IFNs), a group of cellular cyto-kines produced in response to infection by invading patho-
gens, is an extremely powerful component of the host innate im-
mune response that forms the first line of defense against viral
infection. IFNs secreted from virus-infected cells exert their anti-
viral effects by binding to specific receptors on the surface of un-
infected cells. Activated IFN signaling pathways upregulate the
production of hundreds of interferon-stimulated genes (ISGs),
many of which encode proteins that exhibit antiviral activities,
thus creating an antiviral state within these cells (reviewed in ref-
erence 1). Viruses have evolved mechanisms to combat the anti-
viral effects of IFN by encoding proteins with IFN-antagonistic
activities. However, these IFN-antagonistic proteins are rarely
100% efficient, as has been shown for a number of viruses, includ-
ing influenza A virus (2). Therefore, during virus infection, IFN is
likely secreted from some virus-infected cells, which induces an
antiviral state in the neighboring uninfected cells.
To observe the effects of an IFN-induced antiviral state on
influenza virus infection, human lung epithelial A549 cells un-
treated or pretreated with 1,000 U/ml alpha interferon (IFN-)
for 16 h were infected with A/Udorn/72 (H3N2) (Udorn) virus at
a multiplicity of infection (MOI) of 5. Cells were fixed at 12 h
postinfection (h.p.i.) and probed for the expression of both the
viral NS1 protein and MxA by immunofluorescence assay (Fig.
1A). MxA is an IFN-induced protein that is regulated tightly only
by type I or type III IFN signaling (3), and thus, it is often used as
amarker for the IFN-induced antiviral state. The results in Fig. 1A
show that, while virtually all non-IFN-treated cells were positive
for viral antigen, viral replication occurred only in a minority of
IFN-treated cells. However, these cells were also positive forMxA,
suggesting that viral replication was able to overcome the antiviral
state in this minority of cells. Samples fixed at 48 h.p.i. contained
numbers of antigen-positive cells similar to those fixed at 12 h.p.i,
suggesting that, in the majority of cells, the infecting virus was
never able to overcome the IFN-induced block in viral replication
(data not shown).
To determine whether this IFN-mediated antiviral effect could
be overcome by increasing the amount of input virus, IFN-treated
or untreated A549 cells were infected with Udorn virus at a range
of increasing MOIs, fixed at 12 h.p.i., and probed for the expres-
sion of NS1 by flow cytometry (Fig. 1B). The degree of protection
by IFN gradually decreasedwith increasingMOI, although even at
an MOI of 50, only 52% of IFN-treated cells became positive for
viral antigen. Under these experimental conditions, 97% of un-
treated A549 cells became virus antigen positive. These results
indicate that the degree of IFN-mediated inhibition of virus rep-
lication depends on themultiplicity of infection and that influenza
virus is able to overcome the IFN-mediated antiviral state by
swamping the cell with high numbers of infectious virus particles.
To ensure that the above-described findings were not a result
of a virus strain-dependent effect, all experiments were repeated
using the A/WSN/33 (H1N1) (WSN) strain, and all results were
virtually identical to those described above (data not shown).
The initial stages of viral entry after IFN treatment were ana-
lyzed using fluorescent in situ hybridization (FISH) in a virus in-
put assay tomonitor the cellular location of the viral genome from
the initiation of virus-induced endocytosis through to nuclear im-
port. To generate sufficient signal for detection by FISH, the initial
infection required an MOI of 500, which required the use of the
WSN virus strain. IFN-treated or untreated A549 cells were inoc-
ulated with WSN virus at 4°C to synchronize the infection and in
the presence of cycloheximide (CHX) to ensure that only input
viral genomes were detected, due to the global inhibition of pro-
tein synthesis and the prevention of viral replication. At 30 min
after inoculation, the cells were warmed to 37°C to initiate endo-
cytosis, and at 2 h.p.i., FISH was performed using a digoxigenin
(DIG)-labeled probe that hybridized to viral genomic RNA
(vRNA) segment 8. vRNA predominantly localized inside the cell
nuclei in the absence of IFN treatment; however, in themajority of
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IFN-treated cells, vRNA localized outside the nucleus at the peri-
nuclear region (Fig. 1C). Therefore, pretreatment of cells with
IFN- inhibits subsequent influenza virus infection at or imme-
diately prior to the stage of nuclear vRNA import.
The punctate distribution of vRNA in Fig. 1C suggests that
after IFN pretreatment, the incoming viral ribonucleoprotein
complexes (vRNPs) may be retained in late endosomes. To ad-
dress this, naive A549 cells were either treated with IFN or left
untreated for 16 h and subjected to a virus input assay in the pres-
ence of CHX, similar to that described for the FISH experiments
except that vRNP localizationwas detected by immunofluorescence
using an NP-specific monoclonal antibody. Late endosomes were
identified using a rabbit anti-Rab7 monoclonal antibody. Figure
2A shows colocalization of NP and Rab7 for only a minority of
input genomes; however, all areas of punctate NP staining are
immediately adjacent to a late endosome, as determined by Rab7
staining. Thiswas confirmedbymeasuring the fluorescence inten-
sity and distance between areas ofNP andRab7 staining in various
planes through the cell. An example of such analysis shows that, in
a minority of cases, NP and Rab7 overlap (Fig. 2B, white arrow),
which may indicate viral genome trapped inside the late endo-
some. In the majority of cases, the areas of intense NP and Rab7
staining did not overlap (Fig. 2B, asterisks); however, all areas of
intense NP staining were found within 1 m of Rab7 staining.
This may suggest that the viral genome has been released from the
late endosome but its transport to the nucleus is inhibited by one
or more ISG.
To characterize this block in viral replication, the specific ISGs
responsible must be identified. One potential candidate is the
IFN-induced MxA protein, which has been shown to have antivi-
ral activity against a number of DNA and RNA viruses, many of
which are specifically inhibited via MxA interacting with the viral
nucleocapsid proteins (reviewed in reference 4). Previous reports
suggest that MxA has antiviral activity against influenza A virus
(reviewed in references 4 and 5) and that MxA specifically targets
influenza virus nucleoprotein (NP) (6, 7), although the exact
mechanism of this antiviral activity is unknown. To determine
whether MxA plays a role in preventing transport of the viral ge-
nome to the nucleus, an MxA knockdown A549 cell line (A549-
shMxA) was generated using a lentivirus small hairpin RNA
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FIG 1 The effects of IFN treatment on viral replication in A/Udorn/72 virus-infected cells. (A) A549 cells were either left untreated or treated with 1,000 U/ml
IFN- for 16 h and subsequently infected with Udorn virus at an MOI of 5 for 12 h. Cells were then fixed in 5% formaldehyde and permeabilized, and
immunofluorescence assay performed to detect expression of the viral NS1 protein using an NS1-specific polyclonal antiserum and a Texas red-conjugated
secondary antibody (red) or the MxA protein using a specific polyclonal antiserum (Santa Cruz Biotechnology, USA) and a fluorescein isothiocyanate (FITC)-
conjugated secondary antibody (green). Cell nuclei were detected using 4=,6=-diamidino-2-phenylindole (DAPI) (blue). Images were taken at40magnification
using a NikonMicrophot-FXA fluorescence microscope and overlaid using Adobe Photoshop CS5 software. (B) A549 cells were treated with 1,000 U/ml IFN-
for 16 h and subsequently infected with Udorn virus at the indicated MOI for 12 h. Cells were then subjected to flow cytometry analysis in which virus-infected
cells were detected using the anti-NS1 antibody and a phycoerythrin-conjugated secondary antibody. Ten thousand cells were analyzed using a BDFACScan flow
cytometer, and data were subsequently analyzed using FlowJo (Treestar). Results are expressed as the averages of three independent experiments  standard
deviations. Statistical significance was assessed by Student’s t test (*, P  0.0001). (C) Virus input assay of viral genome distribution by fluorescence in situ
hybridization (FISH). A549 cells were treated with 1,000 U/ml IFN- for 16 h and either mock infected or infected with WSN virus at an MOI of 500 in the
presence of 100 g/ml cycloheximide (CHX) at 4°C for 30 min. Cells were incubated at 37°C for 2 h in the presence of CHX, fixed, and stained via FISH using
a DIG-labeled probe (DIG RNA labeling kit; Roche, United Kingdom) specific for vRNA segment 8 (vRNA; red). Cell nuclei were detected using DAPI (blue).
Images were taken at20 and60 magnification using a DeltaVision RT deconvoluting microscope (Applied Precision).
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(shRNA) expression system. Immunoblot and immunofluores-
cence analysis were used to determine the extent of MxA knock-
down in A549-shMxA cells (Fig. 3A and B). Naive A549 cells and
A549-shMxA cells were treated with 1,000 U/ml IFN- for 16 h,
and cells were either lysed for immunoblot assay or fixed for im-
munofluorescence assay with a monoclonal anti-MxA antibody.
In contrast to naive A549 cells, MxA could not be detected in
A549-shMxA cells (Fig. 3A and B); however, the expression of
STAT1 was induced, thereby confirming that A549-shMxA cells
were still able to respond to IFN (Fig. 3A).
Naive A549 or A549-shMxA cells were either treated with IFN
or left untreated for 16 h and subjected to a virus input assay in the
presence of CHX. In untreated A549-shMxA cells, NP was pre-
dominantly observed in the nucleus (Fig. 3B). However, in con-
trast to naive A549 cells after IFN treatment, the vRNPs were effi-
ciently imported into the nucleus of A549-shMxA cells. Therefore,
depletion of MxA prevented the IFN-mediated retention of viral
genome outside the nucleus.
To determine whether MxA expression alone is sufficient for
this effect, anMxA-overexpressing cell line (A549-MxA) was gen-
erated and the expression ofMxAwas determined by immunoblot
and immunofluorescence assays (Fig. 3C and D). MxA accumu-
lated in the cytoplasm of A549-MxA cells with a granular staining
pattern similar to that observed in naive A549 cells treated with
IFN (Fig. 3B). A virus input assay demonstrated that the distribu-
tion of vRNPs in both untreated and IFN-treated A549-MxA cells
was similar to that in naive A549 cells, suggesting that MxA over-
expression alone is not sufficient to prevent the transport of the
viral genome to the nucleus (Fig. 3D).
It was possible that the exogenously expressed MxA protein in
A549-MxA cells was nonfunctional. To address this issue, a stable
cell line was created in which codon-optimized MxA (coMxA)
was introduced into A549-shMxA cells (A549-shMxA/coMxA
cells). The nucleotide sequence of the coMxA gene contains
multiple synonymous substitutions such that no shRNA-comple-
mentary sequences are present. Due to the shRNA-mediated
knockdown of endogenous MxA, only coMxA is expressed in
A549-shMxA/coMxA cells either with or without IFN treatment
(Fig. 4A and B). In a virus input assay, incoming vRNPs were
localized in the nucleus of all A549-shMxA/coMxA cells without
IFN treatment, regardless of the expression level of coMxA. After
IFN treatment, vRNPs were localized in the nucleus of cells dis-
playing low or undetectable levels of coMxA. However, in cells
expressing high levels of coMxA, the vRNPs were predominantly
localized to the cytoplasm (Fig. 4B), indicating that the ability of
IFN to block the transport of influenza virus vRNPs to the nucleus
was restored by reintroducing MxA into MxA knockdown cells.
Despite the fact that MxA expression is required to prevent
vRNP transport to the nucleus, overexpression of MxA alone is
insufficient to account for the observed block. It is possible that a
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FIG 2 IFN treatment results in the retention of viral genome either inside or in the immediate vicinity of late endosomes. (A) Virus input assay. Naive A549 cells
were either left untreated or treated with 1,000 U/ml IFN- for 16 h and subsequently infected with WSN virus at an MOI of 500 in the presence of 100 g/ml
CHX at 4°C for 30 min. Cells were then incubated at 37°C for 2 h in the presence of CHX, fixed in 5% formaldehyde, permeabilized, and subjected to
immunofluorescence analysis. The cellular distribution of NP (red) was determined using an NP-specificmonoclonal antibody (Abcam, United Kingdom), and
the expression of the late endosomalmarker Rab7 (green) was analyzed using a Rab7-specificmonoclonal antiserum (Abcam, United Kingdom). Cellular nuclei
were visualized using DAPI (blue). Images were taken at63 magnification using a Zeiss Pascal 510 confocal microscope and LSM 5 Exciter software. Images
were processed using LSM 5 Image Examiner software (Zeiss). The plasma membrane is outlined in white based on the differential interference contrast (DIC)
image of the selected cells; the outline was overlaid onto the images using Photoshop CS5 software. (B) The distribution of high levels of NP (red) and Rab7
(green) fluorescence intensity through various planes of infected cells was determined using LSM 5 Image Examiner software. An example of this analysis is
shown. The fluorescence intensities of NP (red) and Rab7 (green) along the red line through the selected cell are plotted in the histogram. The distance covered
along the red line is indicated on the x axis. Peaks of NP and Rab7 that are immediately adjacent to each other are highlighted by asterisks, and a peak of
colocalization is highlighted by the white arrow. a.u, arbitrary units.
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form of IFN-induced modification of MxA is required for its an-
tiviral activity. However, amore likely explanation is that there are
other IFN-induced auxiliary molecules that act in conjunction
withMxA to restrict vRNPnuclear import, which is implied by the
data shown in Fig. 4C. Udorn virus was titrated by standard
plaque assay in untreated or IFN-pretreated cells, and plaque
numbers were quantified at 4 days postinfection (Fig. 4C). Com-
pared to the results for untreated naive cells, there was a 74%
reduction in the number of plaques in untreatedMxA-expressing
cells, suggesting that MxA exhibited antiviral activity in the ab-
sence of IFN treatment. However, the plaque number was still
4-fold higher in untreated MxA-expressing cells than in IFN-
treated naive cells. IFN treatment of naive cells resulted in a 15-
fold reduction in plaque number, whereas inMxA knockout cells,
there was only a 5-fold reduction in plaque number after IFN
treatment. However, the plaque number was only 18% that of
untreated naive cells, suggesting that the plaque reduction in IFN-
treated A549-shMxA cells was as a result of at least one ISG prod-
uct other thanMxA. These findings suggest that at least one other
ISG product is required alongside MxA to cause the inhibitory
effect on influenza virus replication observed after IFN treatment.
The cellular location and appearance of the input viral genome
after IFN treatment is suggestive of location in or in the immediate
vicinity of the endosome in which the virus entered the cell. A
similar phenomenon has been reported upon the expression of
IFN-inducible transmembrane protein 3 (IFITM3) (8), a protein
with known antiviral activity against influenza A viruses (8–10).
IFITM3 expression restricts input viral genome to the endosome
by preventing viral fusion, and it was therefore suggested that
IFITM3 is necessary and sufficient for blocking the nuclear import
of influenza vRNPs (8). However, our data suggest that IFITM3
cannot be sufficient for this effect, as in cells lacking MxA, vRNPs
are still efficiently imported into the nucleus after IFN treatment
(Fig. 3B). We have observed that the expression of either MxA or
IFITM3 has a similar effect on plaque number in A549 cells, and
we noted an enhanced antiviral effect when both IFITM3 and
MxA are overexpressed (Fig. 4C). We therefore suggest that, al-
though IFITM3 is undeniably important in preventing influenza
virus infection, MxA also has a significant and profound effect on
preventing transport of the viral genome to the nucleus.
Previous work regarding the antiviral effects of humanMxA in
a mouse cell line indicated a role of MxA in blocking influenza A
virus replication after the stage of primary transcription (11), pos-
sibly by interacting with the viral NP and preventing it from en-
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FIG 3 The effects of MxA depletion and overexpression on nuclear import of viral genomic RNA. (A) Naive A549 and A549-shMxA cells were either left
untreated or treated with 1,000 U/ml IFN- for 16 h. Cells were lysed, and protein content was analyzed by SDS-PAGE and immunoblotting using primary
antibodies specific for MxA and STAT1. -Actin was analyzed as a loading control. (B) Virus input assay. Naive A549 and A549-shMxA cells were either left
untreated or treated with 1,000 U/ml IFN- for 16 h and subsequently mock infected (uninfected) or infected withWSN virus at anMOI of 500 in the presence
of 100g/ml CHX at 4°C for 30 min. Cells were then incubated at 37°C for 2 h in the presence of CHX, fixed in 5% formaldehyde, permeabilized, and subjected
to immunofluorescence analysis. The cellular distribution of NP (red) was determined using an NP-specific monoclonal antibody (Abcam, United Kingdom),
and the expression of MxA (green) was analyzed using the MxA-specific polyclonal antiserum. Images were taken at 40 magnification using a Nikon
Microphot-FXA fluorescence microscope and overlaid using Adobe Photoshop CS5 software. (C) Naive A549 and A549-MxA cells were either left untreated or
treatedwith 1,000U/ml IFN- for 16 h. Cells were lysed, and protein contentwas analyzed by SDS-PAGE and immunoblotting using theMxA-specific polyclonal
antiserum. -Actin was analyzed as a loading control. (D) A549-MxA cells were used in a virus input assay as described for panel B.
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tering the nucleus to participate in secondary transcription. This
mechanism ofMxA action is likely, given that NP has been shown
to be the viral target ofMx proteins (7, 12) and a direct interaction
between MxA and influenza A virus NP has been previously de-
scribed (6). However, a recent report in which similar properties
of MxA were examined in primate cells described an antiviral
effect of MxA prior to the stage of primary transcription, as the
levels of all viral RNA species were reduced in infected cells ex-
pressing MxA (13). Here, we show that this alternative antiviral
effect ofMxA at an earlier stage of the viral replication cycle occurs
by preventing the input vRNPs from being transported to the
nucleus. A similar antiviral effect of MxA has previously been
shown against Thogoto virus (14), which suggests that this func-
tion of MxA is effective against orthomyxoviruses in general and,
potentially, against other viruses that replicate within the nucleus.
Interestingly, MxA seems to require one or more additional IFN-
induced factors for preventing the endosomal-nuclear transport
of the influenza A virus genome but not that of Thogoto virus.
Molecular models of the oligomeric MxA protein structure sug-
gest that binding of MxA around vRNPs is entirely possible (15).
This adds to the hypothesis that MxA may be able to interact
directly with incoming vRNPs in an early stage of viral infection,
thereby preventing vRNPs from entering the nucleus. Further
work is required to fully characterize how MxA interacts with
influenza virus proteins/complexes during the various stages of
the viral replication cycle and to elucidate the nature of the puta-
tive MxA cofactor.
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